Conclusions
neurological deficit, HT
Early add-on of Cerebrolysin to reperfusion therapy was safe and significantly decreased the rate of symptomatic HT as well as early neurological deficit. However, no significant effect on day 90 functional outcome was detected. Improvements in the imaging metrics of the infarcted area support the neuroprotective and BBB stabilizing activity of Cerebrolysin.